Measurable Value: The NHS’s True Currency – Here’s How Pharma And Med Tech Can Cash In
The NHS is stretched to breaking point, complex, pressured and driven by urgent demand. In that chaos, one thing cuts through every time; measurable value.
For pharma, medtech and device companies, grasping what this really means, and delivering it at every turn, is the difference between getting heard or getting ignored.
In commercial markets, product features, clinical data and market share steal the spotlight. But in the NHS? Those things matter for sure but they rarely seal the deal.
The NHS doesn’t buy products. It commissions solutions that fix real problems. And those problems are operationally tough, financially tight and clinically critical.
I’m going to break down what measurable value really means in the NHS and why showing it is the key to getting your solution adopted and scaled.
In a system as stretched, complex and demand driven as the NHS, only one thing consistently cuts through the noise, measurable value.
For pharma, medtech and device companies, understanding what this means and delivering it at every step is the difference between being heard and being ignored.
In the commercial world, product features, clinical data and market share often dominate the narrative. But in the NHS, these factors, while important, are rarely decisive. The NHS doesn’t buy products. It commissions solutions that solve problems, problems that are deeply operational, financially constrained and clinically urgent.
This blog explores what measurable value means in the NHS context and how industry can build and prove it to drive sustainable adoption and scale.
Start with the Problem – How Pharma and Med Tech can solve NHS Pressure Points
Even the best products in the world don’t sell themselves. You may have robust trial data, NICE guidance support and cost effectiveness models but if NHS leaders don’t see how your offer solves a problem they already care about, it won’t land.
This is why measurable value begins with problem definition. It’s not about asking, “what can we sell them?” It’s about asking, “where is the NHS under pressure, and how can we help?”
- Is there a backlog in reviews for long term conditions?
- Is suboptimal treatment creating avoidable A&E admissions?
- Is there a workforce gap that’s preventing service delivery?
If your offer helps tackle one or more of these pain points, you’re in the game. If it doesn’t, it won’t matter how impressive your brochure looks, you’re back in the pavilion.
Measurable value = better outcomes + less pressure
In NHS terms, value is defined through a simple equation:
Better outcomes for patients + less pressure on the system = sustainable change
Let’s break that down.
Better outcomes
These must be quantifiable. That might mean improved blood pressure control, higher asthma control scores, increased uptake of cancer screenings or reduced wound healing times. The NHS won’t accept vague claims, it needs proof that what you’re offering delivers a meaningful clinical benefit.
Less pressure
The second part of the equation is just as critical. NHS teams are exhausted. Any offer that increases workload, adds friction or creates duplication is unlikely to be adopted, even if it’s clinically sound.
That’s why you must reduce system burden, fewer appointments, faster diagnoses, reduced hospital attendances, or support for delivery using existing staff. If you can’t show this, your value proposition is incomplete.
Anchor your Pharma or Med Tech offer in NHS system priorities for adoption success
Another essential filter is strategic alignment. The NHS isn’t just dealing with individual patients, it’s working to deliver national and local priorities, many of which are linked to funding flows, performance targets and political oversight.
This means your solution should map clearly to one or more of the following:
- Core20PLUS5 – reducing health inequalities.
- PCN DES – delivering primary care network priorities.
- Elective recovery – cutting waiting lists.
- Urgent and Emergency Care – improving flow and reducing avoidable admissions.
- Mental health transformation – expanding access and early intervention.
- Ageing well and community care – supporting frailty, falls and chronic condition management.
- Digital and workforce innovation – enabling scalable, integrated care models.
If your pitch, pilot or pathway redesign can explicitly reference how it supports these agendas and use their language to do so, you’ll stand out as relevant, not just well intentioned.
The four filters NHS Decision Makers use to assess project value
Every time you approach a PCN, ICB, a Provider Collaborative or a hospital trust, assume the person you’re speaking to is using a mental checklist to assess your relevance. In my upcoming book Embedded, (launching this autumn) I boil this down to four filters:
- Does it improve patient outcomes? Is there a clear, evidence based benefit for patients?
- Does it reduce workload? Will it save time for GPs, nurses or hospital teams?
- Does it protect or grow income? Can it be delivered through existing income streams like Enhanced Access, QOF, or ARRS?
- Can it be delivered with available workforce? Is it realistic, or does it assume more capacity than currently exists?
If you pass all four, you’re likely to get a second meeting. If you fail on one or more, expect resistance or indifference.
Why proving value with data is key to NHS Adoption for Pharma and Med Tech
The most common mistake I see companies make is assuming the NHS will take their word for it. But in a system where funding is scarce and scrutiny is high, value must be demonstrated in context.
That means real world evaluation. Not theoretical models. Not promises. Actual metrics.
Build a basic evaluation model:
- Cycle 1: Capture baseline data (referrals, outcomes, costs, satisfaction).
- Intervention: Implement your solution with support, training and templates.
- Cycle 2: Repeat the audit and compare results.
- Dashboard: Present the findings visually, ideally a one page summary.
Even a simple two cycle audit, recognised by the CQC, is more powerful than any claims in your brochure. Because now, you’re not asking the NHS to trust you, you’re showing them what’s already worked.
Workforce aware design = measurable value
You could have the best innovation in the world but if there’s no one available to deliver it, it won’t get adopted.
That’s why value is only real if it fits within the workforce constraints of the NHS.
This includes:
- Designing services around ARRS funded roles (clinical pharmacists, care coordinators, etc).
- Supporting task shifting to nurses or allied health professionals.
- Delivering via Enhanced Access hours (evenings and weekends).
- Offering remote or group based delivery models.
If your solution eases the workforce burden, or at the very least doesn’t add to it, it’s more likely to be welcomed.
Be pathway centric, not product focused
The NHS doesn’t commission products in isolation. It funds pathways, integrated systems of care that span multiple roles, services and organisations.
That’s why you must frame your offer not as “a device that…” or “a medicine that…”, but as part of a redesigned pathway.
Instead of saying “Our wearable device detects atrial fibrillation,” you say: “We support PCNs to identify undiagnosed AF in high risk populations during Enhanced Access clinics, using trained ARRS roles and feeding results directly into treatment pathways aligned with national cardiovascular prevention priorities.”
That’s what measurable value sounds like in an NHS meeting.
No matter how strong your model, if it hasn’t been shaped with NHS partners, it may be rejected as “top down.” Co-design creates not just buy-in, but ownership. And that’s a form of value the NHS understands.
Bring standard operating procedures (SOPs). Offer editable templates. Run workshops. Use local data. Allow for tweaks that reflect local context. Co-designed solutions are more credible, more resilient, and far more likely to be scaled.
Scale your offer to the NHS with simple, replicable packaging
Even if your pilot delivers impressive results, it won’t scale unless it’s replicable.
That means packaging your offer with:
- SOPs.
- Training modules.
- Coding templates.
- Evaluation tools.
- Patient communications.
- FAQs for IG and contracting teams.
If you make it easy to say yes, you dramatically increase the likelihood of spread across PCNs, places and ICSs.
Final thoughts – measurable value is the key to success
The NHS is not looking for more products. It’s looking for partners who can help it deliver.
That means aligning with what matters now, speaking the language of impact and efficiency, designing for feasibility as opposed to fantasy and embedding evaluation from day one
Measurable value is not a slogan. It’s the currency of adoption. If you want to win in the NHS, don’t just be innovative. Be relevant. Be useful. Be measurable.
Want more real world tactics to succeed in the NHS?
Embedded: How Pharma, MedTech, and Device Companies Can Get Their Products into NHS Pathways and Stay There – the practical playbook for NHS market access – is publishing September 2025.
Visit www.scottmckenzieconsultancy.com for exclusive resources, real world case studies, and to sign up to my newsletter, and podcast. All designed to help pharma, medtech, and device companies thrive in today’s NHS.
Scott McKenzie helps pharmaceutical, medical technology and device firms get their products and services in front of the right NHS decision-makers. In 2023 alone, he helped land 53 new NHS projects and he added a further 28 in 2024. His 12-month coaching and mentorship programme – revamped and expanded for 2025 – offers tools, extensive NHS customer insights and direct decision-maker introductions to get your projects over the line. Scott’s support is grounded in real world experience of what gets approved, funded and sustained across systems, places and provider collaboratives, turning strategy into impact and frustration into progress. Find out more here.